Treatment outcomes and prognostic factors of feline splenic mast cell tumors: A multi‐institutional retrospective study of 64 cases

Evans, Barbara J.; O'Brien, D; Allstadt, Sara D.; Gregor, Thomas P.; Sørenmo, Karin U.

doi:10.1111/vco.12305

Cited by 19 publications

(23 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MCTs are the most common cause of splenic disease in cats. Affected cats are usually older than 10 or 11 years and there is no sex predilection (Evans, O'Brien, Allstadt, Gregor, & Sorenmo, ; Sabattini et al, ). The disease frequently involves multiple other viscera and bone marrow.…”

Section: Feline Mctsmentioning

confidence: 99%

“…Splenectomy is the standard therapy for cats with splenic mastocytosis and provides longer disease‐free survival than chemotherapy alone (856 days vs. 342 days, respectively) (Evans et al, ). Cats with intestinal MCT historically carry a guarded prognosis and metastasis to mesenteric lymph nodes is common (Barrett et al, ; Morrice, Polton, & Beck, ; Sabattini et al, ).…”

Section: Feline Mctsmentioning

confidence: 99%

“…Cats with pleomorphic poorly differentiated mastocytic MCTs are at risk of unfavourable outcome, hence, post-operative adjuvant radiation therapy and/or chemotherapy has been recommended for these cats (Blackwood, 2015). Splenectomy is the standard therapy for cats with splenic mastocytosis and provides longer disease-free survival than chemotherapy alone (856 days vs. 342 days, respectively) (Evans et al, 2018). Cats with intestinal MCT historically carry a guarded prognosis and metastasis to mesenteric lymph nodes is common (Barrett et al, 2018;Morrice, Polton, & Beck, 2019;Sabattini et al, 2016).…”

Section: Treatment Of Feline Mctmentioning

confidence: 99%

“…The disease frequently involves multiple other viscera and bone marrow. There is no consensus on which factors significantly influence prognosis (Evans et al, ).…”

Section: Feline Mctsmentioning

confidence: 99%

See 3 more Smart Citations

Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment

Tamlin

Bottema

Peaston

2019

Veterinary Medicine & Sci

View full text Add to dashboard Cite

Mast cell neoplasia clinical presentation and biological behaviour vary considerably across mammalian species, ranging from a solitary benign mass to an aggressive systemic malignancy. Mutations in the KIT Proto‐Oncogene Receptor Tyrosine Kinase (KIT) gene are common molecular abnormalities involved in mast cell tumorigenesis. KIT mutations often occur in dog, cat and human neoplastic mast cells and result in altered Kit protein structure and function. In dogs, certain KIT mutations are associated with more malignant and lethal disease. In contrast, KIT mutations in feline and human mast cell neoplasms are not correlated with prognosis, but are of value in diagnosis and treatment planning in humans. KIT genetic abnormalities have not been well investigated in other species, although aberrant cytoplasmic Kit protein staining detected in neoplasms of the ferret, horse and cow resembles aberrant Kit staining patterns detected in neoplastic mast cells of dogs, cats and humans. Mutations within KIT are classified as either regulatory‐type or enzymatic pocket‐type mutations according to their location within the KIT Proto‐Oncogene. Mutations within the enzymatic pocket domain confer tumour resistance to tyrosine kinase inhibitors (TKIs). Hence, knowledge of tumour KIT mutation status adds valuable information for optimizing patient treatment strategies. The use of TKIs in combination with conventional chemotherapeutics has opened a new treatment avenue for patients unresponsive to existing drugs. This review highlights the similarities and differences of mast cell neoplasia in mammals with a special focus on the involvement of KIT in the canine and feline forms in comparison to human mast cell neoplasia.

show abstract

Section: Feline Mctsmentioning

confidence: 99%

Section: Feline Mctsmentioning

confidence: 99%

Section: Treatment Of Feline Mctmentioning

confidence: 99%

“…The disease frequently involves multiple other viscera and bone marrow. There is no consensus on which factors significantly influence prognosis (Evans et al, ).…”

Section: Feline Mctsmentioning

confidence: 99%

See 2 more Smart Citations

Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment

Tamlin

Bottema

Peaston

2019

Veterinary Medicine & Sci

View full text Add to dashboard Cite

show abstract

“…13), a high percentage of mast cell tumors in cats are negative for different immunohistochemical markers, including c-kit [40], which can impede a diagnosis in poorly differentiated cases. Prognostic factors are not entirely clear in cats, but splenectomy has been recommended for feline splenic mast cell tumors [41,42]. Careful exploration of the pancreas is recommended because of the risk of incomplete resection of splenic tissue in the case of affected accessory spleens, as in our case.…”

Section: Discussionmentioning

confidence: 87%

Clinical and Pathological Data of 17 Non-Epithelial Pancreatic Tumors in Cats

Törner

Staudacher

Steiger

et al. 2020

Veterinary Sciences

View full text Add to dashboard Cite

Tumors of mesenchymal origin are rarely reported in the pancreas. Therefore, this study characterized 17 feline non-epithelial pancreatic tumors, including clinical data, histopathology, and immunohistochemistry. Seventeen feline pancreatic tissue samples were investigated histopathologically and immunohistochemically. Selected pancreatic and inflammatory serum parameters, e.g., feline pancreatic lipase immunoreactivity (fPLI), 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6′-methylresorufin) ester (DGGR) lipase and serum amyloid A (SAA), were recorded, when available. The neoplasms were characterized as round (n = 13) or spindle (n = 4) cell tumors. Round cell tumors included 12 lymphomas and one mast cell tumor in ectopic splenic tissue within the pancreas. Lymphomas were of T-cell (n = 9) or B-cell (n = 3) origin. These cats showed leukocytosis (3/3) and increased fPLI (5/5), DGGR lipase (3/5) and SAA (4/5) values. Spindle cell tumors included two hemangiosarcomas, one pleomorphic sarcoma and one fibrosarcoma. The cat with pleomorphic sarcoma showed increased SAA value. Overall survival time was two weeks to seven months. These are the first descriptions of a pancreatic pleomorphic sarcoma and a mast cell tumor in accessory spleens within feline pancreas. Although rare, pancreatic tumors should be considered in cats presenting with clinical signs and clinical pathology changes of pancreatitis. Only histopathology can certainly distinguish solitary pancreatitis from a neoplasm with inflammation.

show abstract

Hemolymphatic System

Worley¹

2022

Veterinary Surgical Oncology

View full text Add to dashboard Cite

Treatment outcomes and prognostic factors of feline splenic mast cell tumors: A multi‐institutional retrospective study of 64 cases

Abstract: Splenectomy (+/- chemotherapy) significantly prolongs survival in cats with mast cell tumors. The role of chemotherapy remains unknown.

Cited by 19 publications

References 10 publications

Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment

Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment

Clinical and Pathological Data of 17 Non-Epithelial Pancreatic Tumors in Cats

Hemolymphatic System

Contact Info

Product

Resources

About